The Critical Care Center (CCC) at Memorial Sloan Kettering Cancer Center, established in February 2017, advances clinical care, research, and education in critical care medicine through collaboration with a multitude of disciplines. Current collaborations with the Bone Marrow Transplant and Solid Tumor Services are looking at how treatments with an immune-mediated cytokine (interleukin-7) and a toll-like receptor 4 (TLR4) antagonist (eritoran) might influence immune activity in the context of COVID-19 and cancer, which could lead to important insights in treating COVID-19 in general and, more specifically, improve the outcomes of oncology patients with COVID-19. Previous interdisciplinary collaborations have culminated in numerous initiatives. These include working with the Bone Marrow Transplant Service to analyze the short- and long-term outcomes of allogeneic stem cell transplant patients admitted to the Intensive Care Unit (ICU); with the Infectious Diseases Service to explore the role of antimicrobial stewardship programs in de-escalation of initial broad-spectrum antibiotics in adult cancer patients with severe sepsis; with the Department of Laboratory Medicine to investigate the utility of novel biomarkers of infection, such as procalcitonin and cytokines as predictors of bloodstream infections, and supportive modalities in critically ill cancer patients; and with the Department of Neurology to better understand the neurologic manifestations of COVID-19, including a targeted proteomics analysis of the cerebrospinal fluid. In addition, our previous research has included collaboration with top research facilities, such as Cleveland Clinic, MD Anderson Cancer Center, and Mayo Clinic, describing the ICU practices in the management of toxicities associated with chimeric antigen receptor (CAR) T cell therapy and immune checkpoint inhibitors. The CCC team has adopted a multidisciplinary approach at research and continues to collaborate with numerous departments within MSK to advance research and initiatives. Our goal remains to advance the current understanding of critically ill cancer patients and utilize groundbreaking research to impact and advance their care delivery.